CN101062032A - 一种舒巴坦钠抗菌素复合物及其制备工艺 - Google Patents
一种舒巴坦钠抗菌素复合物及其制备工艺 Download PDFInfo
- Publication number
- CN101062032A CN101062032A CN 200610075961 CN200610075961A CN101062032A CN 101062032 A CN101062032 A CN 101062032A CN 200610075961 CN200610075961 CN 200610075961 CN 200610075961 A CN200610075961 A CN 200610075961A CN 101062032 A CN101062032 A CN 101062032A
- Authority
- CN
- China
- Prior art keywords
- sulbactam sodium
- liposome
- sodium
- weight
- bacteriophage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 title claims description 99
- 229960000614 sulbactam sodium Drugs 0.000 title claims description 99
- 241001515965 unidentified phage Species 0.000 title claims description 30
- 238000000034 method Methods 0.000 title description 3
- 239000002502 liposome Substances 0.000 claims abstract description 70
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 26
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 26
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 34
- 239000008176 lyophilized powder Substances 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 19
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 19
- 238000009210 therapy by ultrasound Methods 0.000 claims description 18
- 230000003115 biocidal effect Effects 0.000 claims description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 14
- 235000003969 glutathione Nutrition 0.000 claims description 14
- 229960003180 glutathione Drugs 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000004108 freeze drying Methods 0.000 claims description 12
- 238000005374 membrane filtration Methods 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- NRQPHQVKGKTLAW-UHFFFAOYSA-N 2-(propanoylamino)-2-sulfanylacetic acid Chemical compound CCC(=O)NC(S)C(O)=O NRQPHQVKGKTLAW-UHFFFAOYSA-N 0.000 claims description 8
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims description 8
- 229950002441 glucurolactone Drugs 0.000 claims description 8
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 claims description 7
- 229960002793 amoxicillin sodium Drugs 0.000 claims description 7
- 229960002417 cefoperazone sodium Drugs 0.000 claims description 7
- ILVPFTMKCHREDJ-UHFFFAOYSA-N methyl 5-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1F ILVPFTMKCHREDJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 6
- 229910052708 sodium Inorganic materials 0.000 abstract description 4
- 239000011734 sodium Substances 0.000 abstract description 4
- 230000000857 drug effect Effects 0.000 abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 3
- 239000002131 composite material Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 21
- 230000003203 everyday effect Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000010253 intravenous injection Methods 0.000 description 14
- 239000002994 raw material Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000012913 prioritisation Methods 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
哌拉西林钠/舒巴坦钠混合物 | 75 | 3 | 21 | 19 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100759614A CN101062032B (zh) | 2006-04-25 | 2006-04-25 | 一种舒巴坦钠抗菌素复合物及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100759614A CN101062032B (zh) | 2006-04-25 | 2006-04-25 | 一种舒巴坦钠抗菌素复合物及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101062032A true CN101062032A (zh) | 2007-10-31 |
CN101062032B CN101062032B (zh) | 2011-06-08 |
Family
ID=38963452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100759614A Expired - Fee Related CN101062032B (zh) | 2006-04-25 | 2006-04-25 | 一种舒巴坦钠抗菌素复合物及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101062032B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012429A (zh) * | 2012-12-28 | 2013-04-03 | 吴秋萍 | 一种新型阿莫西林钠化合物及其与舒巴坦钠化合物的组合物 |
CN103142588A (zh) * | 2013-04-09 | 2013-06-12 | 黑龙江省汇丰动物保健品有限公司 | 一种注射用阿莫西林钠舒巴坦钠及其制备方法 |
CN104586843A (zh) * | 2014-12-25 | 2015-05-06 | 重庆福安药业(集团)股份有限公司 | 注射用阿莫西林钠舒巴坦钠复方药物组合物及其制备工艺 |
CN105853441A (zh) * | 2016-04-05 | 2016-08-17 | 海南合瑞制药股份有限公司 | 一种头孢哌酮钠舒巴坦钠组合物 |
WO2017117882A1 (zh) * | 2016-01-04 | 2017-07-13 | 四川制药制剂有限公司 | 一种哌拉西林钠与舒巴坦钠的药物组合物 |
CN107823154B (zh) * | 2017-11-21 | 2021-02-19 | 上海金城素智药业有限公司 | 头孢克洛制剂及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1623544A (zh) * | 2003-12-01 | 2005-06-08 | 沈阳华泰药物研究有限公司 | 一种注射用阿莫西林舒巴坦的制备 |
-
2006
- 2006-04-25 CN CN2006100759614A patent/CN101062032B/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012429A (zh) * | 2012-12-28 | 2013-04-03 | 吴秋萍 | 一种新型阿莫西林钠化合物及其与舒巴坦钠化合物的组合物 |
CN103012429B (zh) * | 2012-12-28 | 2014-12-31 | 吴秋萍 | 一种新型阿莫西林钠化合物及其与舒巴坦钠化合物的组合物 |
CN103142588A (zh) * | 2013-04-09 | 2013-06-12 | 黑龙江省汇丰动物保健品有限公司 | 一种注射用阿莫西林钠舒巴坦钠及其制备方法 |
CN104586843A (zh) * | 2014-12-25 | 2015-05-06 | 重庆福安药业(集团)股份有限公司 | 注射用阿莫西林钠舒巴坦钠复方药物组合物及其制备工艺 |
WO2017117882A1 (zh) * | 2016-01-04 | 2017-07-13 | 四川制药制剂有限公司 | 一种哌拉西林钠与舒巴坦钠的药物组合物 |
CN105853441A (zh) * | 2016-04-05 | 2016-08-17 | 海南合瑞制药股份有限公司 | 一种头孢哌酮钠舒巴坦钠组合物 |
CN105853441B (zh) * | 2016-04-05 | 2018-11-27 | 海南合瑞制药股份有限公司 | 一种头孢哌酮钠舒巴坦钠组合物 |
CN107823154B (zh) * | 2017-11-21 | 2021-02-19 | 上海金城素智药业有限公司 | 头孢克洛制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101062032B (zh) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101062032A (zh) | 一种舒巴坦钠抗菌素复合物及其制备工艺 | |
CN1919363A (zh) | 新型透析浓缩制剂 | |
CN1297274C (zh) | 药物组合物 | |
CN1267220A (zh) | 凝胶化组合物 | |
CN1896107A (zh) | 类天蚕素a-马盖宁杂合基因工程抗菌肽 | |
CN1486177A (zh) | 用于结合唾液、胃和大肠中乙醛的方法与制剂 | |
CN1529614A (zh) | 减少癌症患者的化疗副作用的方法 | |
CN1840171A (zh) | 慢性肾病营养液及其制备方法 | |
CN1771902A (zh) | 多功能保健牙膏及其生产工艺 | |
CN1190186C (zh) | 在多隔室容器中的医用碳水化合物溶液和亚硫酸盐稳定剂及其应用 | |
CN1033000A (zh) | 营养品食物和药品的镁添加剂 | |
CN101036642A (zh) | 银杏内酯b纳米脂质体药物及其制备方法 | |
CN1868463A (zh) | 一种α-硫辛酸或其衍生物的缓释制剂及其制备方法 | |
CN1030527A (zh) | 抗球虫组合物 | |
CN1103782A (zh) | 眼局部给药的抗***反应的药物组合物 | |
CN101062024A (zh) | 一种硫普罗宁组合药物及其制备方法 | |
CN1166402C (zh) | 一种具有保健作用的中药组合物 | |
CN1887271A (zh) | 阿奇霉素脂质体组合药物及其制备方法 | |
CN1543987A (zh) | 一种利用梅花鹿胎制备活性肽-鹿胎素的方法及应用 | |
CN1084061A (zh) | 白内障治疗剂及其制备方法 | |
CN1861626A (zh) | 一种含有甘草次酸或其衍生物的金属盐类药物及其制备方法 | |
CN1907293A (zh) | 一种治疗肺炎的组合药物及其制备方法 | |
CN1500487A (zh) | 左西替利嗪伪麻黄碱复方口服制剂及制备方法 | |
CN1927206A (zh) | 氯诺昔康注射用组合物及其制备方法 | |
CN1765364A (zh) | 盐酸洛拉曲克的脂质体制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HU'NAN KANGDOU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIU XIANGHUA Effective date: 20121114 Free format text: FORMER OWNER: CAI HAIDE Effective date: 20121114 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410329 CHANGSHA, HUNAN PROVINCE TO: 426100 YONGZHOU, HUNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121114 Address after: The 426100 town Qiyang County of Hunan province Wu Day Road No. 1 Patentee after: Hunan Kangdu Pharmaceutical Co., Ltd. Address before: 410329 Liuyang biological pharmaceutical industry park Hunan Hunan Kang Yuan Pharmaceutical Co., Ltd. Patentee before: Liu Xianghua Patentee before: Cai Haide |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110608 Termination date: 20180425 |
|
CF01 | Termination of patent right due to non-payment of annual fee |